    [Federal Register Volume 85, Number 168 (Friday, August 28, 2020)]
    [Notices]
    [Pages 53390-53391]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 2020-18988]

    -----------------------------------------------------------------------

    DEPARTMENT OF HEALTH AND HUMAN SERVICES

    National Institutes of Health

    Prospective Grant of an Exclusive Patent License: Anti-CD56 as an
    Antibody-Drug Conjugate (``ADC'') or Non-ADC To Target Glioblastoma
    Either Alone or in Combination With Other Potential Immuno-Oncology
    Drugs.

    AGENCY: National Institutes of Health, Health and Human Services.
    (HHS).

    ACTION: Notice.

    -----------------------------------------------------------------------

    SUMMARY: The National Cancer Institute, an institute of the National
    Institutes of Health, Department of Health and Human Services, is
    contemplating the grant of an Exclusive Patent License to practice the
    inventions embodied in the Patents and Patent Applications listed in
    the Supplementary Information section of this notice to Connectyx
    Technologies Holdings Group (``Connectyx'') located in Boca Raton, FL.

    DATES: Only written comments and/or applications for a license which
    are received by the National Cancer Institute's Technology Transfer
    Center on or before September 14, 2020 will be considered.

    ADDRESSES: Requests for copies of the patent application, inquiries,
    and comments relating to the contemplated an Exclusive Patent License
    should be directed to: Jasmine Yang, Ph.D., Senior Licensing and
    Patenting Manager at Telephone: (240)-276-5530 or at Email:
    jasmine.yang@nih.gov.

    SUPPLEMENTARY INFORMATION:

    Intellectual Property

    (1) U.S. Provisional Patent Application No. 62/119,707 filed July 31,
    2015. HHS Ref No. E-221-2015-0-US-01
    (2) PCT Application No. PCT/US2016/044777 filed 07/29/2016. HHS Ref.
    No. E-221-2015-0-PCT-02
    (3) U.S. Patent No. 10,548,987 issued February 02, 2020 (Patent
    Application No. 15/747,620 filed January 25, 2018). HHS Ref. No. E-221-
    2015-0-US-03.

        The patent rights in these inventions have been assigned and/or
    exclusively licensed to the government of the United States of America.
        The prospective exclusive license territory may be worldwide and
    the field of use may be limited to the use of Licensed Patent Rights
    for the following: Anti-CD56 as an antibody-drug conjugate (``ADC'') to
    target and treat glioblastoma either alone or in

    [[Page 53391]]

    combination with other potential immuno-oncology drugs.
        This technology discloses the composition of an ADC comprising a
    drug conjugated to CD56-specific monoclonal antibodies, m900 and m906,
    or an antigen-binding fragment, wherein the drug comprises a cytotoxic
    agent, including but not limited to PBD, and to methods of using the
    ADCs for treating neuroblastoma, small-cell lung cancer, multiple
    myeloma, acute myeloid leukemia, NK-T lymphoma, and neuroendocrine
    cancer. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
    part 404. The prospective exclusive license will be royalty bearing,
    and the prospective exclusive license may be granted unless within
    fifteen (15) days from the date of this published notice, the National
    Cancer Institute receives written evidence and argument that
    establishes that the grant of the license would not be consistent with
    the requirements of 35 U.S.C. 209 and 37 CFR part 404.
        In response to this Notice, the public may file comments or
    objections. Comments and objections, other than those in the form of a
    license application, will not be treated confidentially, and may be
    made publicly available.
        License applications submitted in response to this Notice will be
    presumed to contain business confidential information and any release
    of information in these license applications will be made only as
    required and upon a request under the Freedom of Information Act, 5
    U.S.C. 552.

        Dated: August 20, 2020.
    Richard U. Rodriguez,
    Associate Director, Technology Transfer Center, National Cancer
    Institute.
    [FR Doc. 2020-18988 Filed 8-27-20; 8:45 am]
    BILLING CODE 4140-01-P